Looking beyond Wall Street's top -and-bottom-line estimate forecasts for ResMed (RMD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the ...

Read about ResMed, Abbott Laboratories and more in the latest Market Talks covering the Health Care sector.

Shares of ResMed Inc. RMD shed 1.16% to $211.49 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to 5,275.70 and Dow ...

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mizuho analyst Anthony Petrone lowered the firm’s price target on ResMed (RMD) to $265 from $280 and keeps an Outperform rating on the shares ...

The risk of both all-cause deaths and those caused by cardiovascular conditions in OSA patients is significantly reduced with the use of CPAP therapy.

Donald Trump’s radical agenda to up-end the global trade order is part of a much broader structural reset and, crucially, he still has the support of Middle America to push ahead, investors say.

Australian healthcare stocks are navigating a challenging landscape from an onslaught of tariffs under the Trump administration, but Morgan Stanley has highlighted CSL and ResMed as the strongest ...

Morgan Stanley analyst David Bailey maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD – ...

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor ...

Sleep patient volume growth was slower in the last 12 months but is expected to improve in the next 12 months, according to the 1Q25 HME Sleep and Oxygen Survey from Needham.

ResMed Inc. (RMD), headquartered in San Diego, California, specializes in designing and delivering medical devices and ...